Banking Law and Self-Assembling Technology Finance in Spain

1. Introduction

Self-assembling technology finance in Spain concerns financing technologies in which components are designed to organise, combine or form structures with limited direct human intervention. Examples can arise in:

• nanotechnology and advanced materials;
• biotechnology and biomaterials;
• microelectronics;
• programmable materials;
• modular robotics;
• pharmaceutical research;
• self-assembling molecular systems; and
• advanced manufacturing.

Spain has no standalone banking statute specifically governing loans for self-assembling technology. Financing instead falls within ordinary Spanish and EU banking law together with rules governing intellectual property, product safety, biotechnology, nanomaterials, chemicals, environmental protection, AI/robotics where applicable, State aid and research funding.

A typical structure is:

Researchers / technology company → SPV/company → equity + bank/EIB/public finance → R&D → pilot production → regulatory approval → commercial production → revenues → debt repayment

Because many projects are experimental, banks face substantially greater technology and commercialisation risk than in ordinary asset-backed lending.

2. What Is Self-Assembling Technology?

Self-assembly broadly describes processes where components organise into an intended structure through their inherent interactions or programmed characteristics.

For financing purposes, it is useful to distinguish four categories.

Molecular self-assembly

Molecules form larger organised structures.

Potential applications include:

• medicine;
• coatings;
• electronics;
• sensors; and
• advanced materials.

Nanotechnology

Nanoparticles or nanoscale structures may assemble into functional materials.

Biological self-assembly

Biological components may be used to form:

• tissues;
• biomaterials;
• diagnostic structures; or
• research platforms.

Robotic or modular assembly

Physical modules may connect or reorganise with significant automation.

The legal regime changes according to the actual application.

3. Main Financing Structures

Spanish self-assembling technology companies can potentially use:

• venture capital;
• bank loans;
• venture debt;
• equipment financing;
• R&D loans;
• public grants;
• EIB/EIF financing;
• project finance for mature industrial facilities;
• corporate bonds;
• convertible instruments; and
• strategic-investor funding.

An early-stage laboratory will normally have a very different financing profile from an established manufacturer.

4. Why Conventional Bank Financing Is Difficult

Suppose a startup has:

• laboratory equipment: €2m;
• patents: potentially €30m;
• cash: €1m;
• no commercial revenue.

It requests:

€20 million bank loan.

A conventional bank faces a problem.

The company's principal value depends on whether the technology actually becomes commercially successful.

If development fails:

• patent value may collapse;
• specialised equipment may have low resale value;
• there may be no receivables;
• commercial contracts may disappear.

Consequently, early-stage self-assembly projects are commonly better suited to substantial equity, grants and risk-sharing finance, with bank debt becoming easier as revenues mature.

5. Spanish Banking Framework

Where Spanish banks provide credit, the general banking framework applies.

Important sources include:

• Law 10/2014 on the regulation, supervision and solvency of credit institutions;
• Royal Decree 84/2015;
• EU Capital Requirements Regulation/Directive framework;
• ECB supervisory requirements for significant institutions;
• Banco de España requirements;
• Spanish contract and security law.

Banks must manage the financing as a credit exposure even if the underlying technology has strategic importance.

6. Credit Risk

A lender should separate at least five risks:

Scientific risk

Will the technology work?

Scale-up risk

Can a laboratory process operate at industrial scale?

Regulatory risk

Can the resulting product legally be marketed?

Commercial risk

Will customers buy it?

Financial risk

Will cash flow be sufficient to repay debt?

A project can succeed scientifically but still fail commercially.

That distinction is crucial for bank lending.

7. Technology Readiness

Banks and institutional investors may examine the project's technology readiness level (TRL) or a comparable development framework.

For example:

Concept → laboratory validation → prototype → pilot → demonstration → commercial production

Debt becomes progressively easier to justify as technical uncertainty declines.

A financing agreement may therefore provide milestone-based drawdowns.

8. Milestone Financing

Suppose a company requires €50 million.

Instead of lending all €50m immediately:

€5m — laboratory validation

↓

€10m — prototype

↓

€10m — successful pilot

↓

€15m — regulatory/commercial milestone

↓

€10m — manufacturing expansion

The bank or financing institution limits its exposure if development fails early.

9. Intellectual Property

Intellectual property is often the most valuable asset.

Relevant rights include:

• patents;
• patent applications;
• software copyright;
• database rights;
• trade secrets;
• know-how;
• licences.

A bank should verify:

1. Who invented the technology?
2. Who owns the patent?
3. Was it developed at a university?
4. Does the company have an exclusive licence?
5. Are third-party patents required?
6. Are employees' rights properly assigned?
7. Are there infringement proceedings?

10. European Patent Law

Many Spanish technology businesses seek patent protection through the European patent system.

Patent protection can increase financing value because competitors can potentially be prevented from commercially exploiting protected inventions within the relevant territorial scope.

However:

A patent is not proof of commercial success.

A technically valid patent may still have little market value.

Banks therefore should not treat patent valuation like ordinary real-estate valuation.

11. Huawei v ZTE — CJEU, C-170/13

Huawei Technologies Co. Ltd v ZTE Corp., C-170/13 is an important EU authority concerning enforcement of standard-essential patents.

The Court addressed the relationship between patent enforcement and EU competition law where the patent holder had made a FRAND commitment.

Financing relevance

The case is not about self-assembling technology or bank lending.

Its importance is that technology companies cannot value patent portfolios without considering:

• licensing obligations;
• competition law;
• enforceability; and
• third-party rights.

A lender relying heavily on IP must therefore conduct more than a simple ownership check.

12. Brüstle v Greenpeace — CJEU, C-34/10

In Oliver Brüstle v Greenpeace eV, the CJEU considered the patentability of inventions involving human embryonic stem cells under the Biotechnology Directive.

Relevance

For biological self-assembling technologies, patentability can be constrained by mandatory legal rules.

This affects financing because a company's assumed IP monopoly may be narrower than its business plan suggests.

The case is especially relevant where the self-assembly technology crosses into biotechnology.

13. International Stem Cell Corporation — CJEU, C-364/13

The CJEU further examined the concept of a human embryo for biotechnology patent purposes in International Stem Cell Corporation v Comptroller General of Patents, C-364/13.

Financing relevance

The decision demonstrates that scientific classification and legal patentability are separate questions.

For biotechnology finance, lenders should therefore obtain specialist patent advice before attributing substantial collateral value to research IP.

14. Spanish Patent Law

Spain's Law 24/2015 on Patents is particularly relevant.

It regulates matters including:

• patents;
• patent ownership;
• licences;
• transfers;
• infringement; and
• patent-related rights.

For a lender, patent due diligence should establish whether the borrower has sufficient legal control over the technology throughout the financing term.

15. University Spin-Offs

Many advanced technologies originate in universities or research institutions.

Suppose researchers develop self-assembling nanomaterials at a Spanish university and create a startup.

The bank must determine whether:

University → owns patent

and

Startup → merely has licence

or

Startup → owns patent outright.

This distinction can dramatically affect collateral and enterprise value.

16. Licence Risk

A company may rely on a licence rather than ownership.

Important provisions include:

• exclusivity;
• territory;
• duration;
• royalties;
• sublicensing;
• change of control;
• insolvency;
• termination;
• performance milestones.

A bank should examine whether borrower default or lender enforcement could cause the licence to terminate.

17. Security Over IP

Where permitted and properly documented, lenders may seek security involving intellectual-property rights.

However, practical enforcement can be difficult.

If a technology company fails, selling a highly specialised patent may produce far less than expected.

Therefore, lenders often prefer a broader security package:

IP + accounts + receivables + equipment + shares + insurance + contractual rights.

18. State Aid and R&D Funding

Self-assembling technologies can qualify for public R&D and innovation support.

EU State-aid rules are therefore particularly important.

Articles 107–109 TFEU govern State aid.

Research support may also operate under EU State-aid exemptions and frameworks for research, development and innovation.

A public grant is not automatically unlawful State aid; its legal treatment depends on its structure.

19. Altmark Trans — CJEU, C-280/00

Altmark established four cumulative conditions relating to compensation for public-service obligations.

It is not a research-finance case.

Its broader relevance is that the legal classification of public money depends on the substantive conditions under which it is provided.

For ordinary R&D grants to technology companies, more specific State-aid rules will generally be more directly relevant.

20. PreussenElektra — CJEU, C-379/98

This case addressed the concept of State resources.

For self-assembly technology finance, it illustrates a fundamental question:

Is a particular support mechanism legally attributable to the State and financed through State resources for Article 107 purposes?

It is an indirect authority rather than a technology-finance case.

21. Stardust Marine — CJEU, C-482/99

France v Commission (Stardust Marine) is relevant where financing comes through a publicly controlled financial institution.

The case deals with State resources and imputability to the State.

If a Spanish public financing institution invests in an advanced-technology company, the terms of that financing may therefore require State-aid analysis.

22. EDF v Commission — CJEU, C-124/10 P

EDF v Commission is important to the market-economy-operator principle.

Where a public entity invests on genuinely commercial terms comparable to those acceptable to a private investor, the State-aid analysis can differ from a subsidised transaction.

This matters for technology companies receiving public equity or loans.

23. EIB and EIF

European institutions can be important in deep-tech financing.

Potential sources include:

• European Investment Bank;
• European Investment Fund;
• InvestEU-supported structures;
• venture-capital funds;
• innovation guarantees.

These mechanisms can help bridge the gap between:

high-risk R&D

and

commercial bankability.

A commercial bank may participate once part of the technology risk is absorbed by equity investors or guarantee mechanisms.

24. EU Research Funding

EU research programmes such as Horizon Europe can support advanced materials, biotechnology, robotics and nanotechnology research.

However, a grant has to be analysed carefully.

It may include:

• eligible-cost requirements;
• milestones;
• reporting;
• audit rights;
• IP conditions;
• repayment/clawback provisions.

Therefore:

Grant award ≠ unrestricted collateral.

25. Nanotechnology Regulation

Self-assembling technology may involve nanomaterials.

Depending on the product, regulation can include:

• REACH chemicals rules;
• occupational safety;
• environmental rules;
• product-specific legislation;
• medical-device rules;
• cosmetics rules;
• food legislation.

The applicable regime depends on what the technology ultimately becomes.

26. REACH

Regulation (EC) No 1907/2006 (REACH) governs registration, evaluation, authorisation and restriction of chemicals.

Where self-assembling materials fall within its scope, compliance can materially affect commercialisation.

A bank should ask:

• Are substances registered where required?
• Are restrictions applicable?
• Is authorisation necessary?
• Are safety data adequate?
• Could future restrictions affect production?

Regulatory non-compliance can reduce the value of the financed technology.

27. Product Liability

A self-assembling product could potentially cause harm after commercialisation.

For example:

• biomaterial failure;
• defective medical product;
• industrial material malfunction;
• autonomous modular system failure.

Product-liability exposure therefore affects:

• insurance;
• reserves;
• financing covenants;
• due diligence.

The EU product-liability framework is especially relevant where advanced software or emerging technologies form part of the product.

28. Medical Applications

If self-assembling technology is used in a medical device, Regulation (EU) 2017/745 may become relevant.

The company may need:

• conformity assessment;
• technical documentation;
• clinical evidence;
• risk management;
• post-market surveillance;
• CE marking.

For a bank:

successful laboratory research ≠ legal market access.

This is why regulatory approval milestones may be conditions to additional loan drawdowns.

29. Biotechnology

Biotechnology projects may also fall within rules concerning:

• genetically modified organisms;
• medicinal products;
• clinical research;
• biological safety;
• ethics;
• environmental release.

A lender should identify the regulatory pathway before relying on forecast commercial revenues.

30. Robotics and AI

Some modular self-assembling systems could incorporate artificial intelligence.

Where an AI system falls within the scope of Regulation (EU) 2024/1689 (EU AI Act), the provider or deployer may have additional regulatory obligations depending on the system's classification and use.

The mere fact that a robot can physically assemble itself does not automatically make it a high-risk AI system.

The actual intended use and AI functionality determine the analysis.

31. Foreign Investment Screening

Advanced materials, nanotechnology, biotechnology and robotics may constitute strategically sensitive technologies.

Spain's FDI screening regime can therefore affect foreign investments in relevant companies.

A proposed acquisition may need regulatory approval before completion.

For acquisition financing, banks may require:

FDI approval as a condition precedent.

This prevents loan funds being advanced for a transaction that cannot legally close.

32. Export Controls

Some self-assembling technologies may have civilian and military applications.

Regulation (EU) 2021/821 establishes the EU dual-use export-control framework.

Possible controlled areas include:

• advanced materials;
• electronics;
• sensors;
• biotechnology;
• manufacturing technology;
• software.

A lender must therefore assess whether projected international revenues depend on export licences.

33. Sanctions

Banks must also consider EU sanctions.

A technology company may face restrictions involving:

• customers;
• investors;
• beneficial owners;
• destination countries;
• dual-use technology;
• research partners.

A valuable export contract can become commercially unusable if performance would violate applicable sanctions.

34. Venture Debt

Venture debt can be useful where a technology company has:

• strong institutional investors;
• valuable IP;
• significant funding rounds;
• credible commercial milestones;
• limited current profits.

A structure might be:

Equity funding: €30m

Venture debt: €10m

The lender may receive:

• interest;
• security;
• financial covenants;
• warrants or another permitted equity-linked element.

The exact legal structure must comply with Spanish corporate, financial and securities rules.

35. Project Finance After Commercialisation

Once self-assembling technology is proven, financing can shift from startup finance to industrial project finance.

For example:

Commercial technology

↓

€300m manufacturing plant

↓

Long-term customer contracts

↓

Predictable cash flow

↓

Bank project finance

At this stage, lenders can rely more heavily on revenue and physical assets rather than speculative future IP value.

36. Offtake Agreements

An industrial project may secure long-term customers.

Example:

A self-assembling materials company agrees to supply:

20,000 tonnes annually for 10 years

to major industrial customers.

The bank examines:

• quantity commitments;
• pricing;
• indexation;
• quality standards;
• termination;
• force majeure;
• customer creditworthiness.

Strong offtake agreements can significantly improve bankability.

37. Environmental Risk

Advanced manufacturing may involve:

• hazardous chemicals;
• nanoparticles;
• industrial waste;
• emissions;
• water use;
• specialist disposal.

Environmental liabilities can survive commercial failure and reduce collateral value.

Banks may therefore require:

• environmental due diligence;
• permits;
• remediation assessments;
• insurance;
• compliance covenants.

38. Insolvency

Spanish insolvency law becomes critical if the technology company fails.

The lender's recovery depends on:

• classification of claims;
• validity of security;
• restructuring;
• insolvency proceedings;
• value of IP;
• licences;
• equipment value.

A technology company can have a high going-concern value but extremely low liquidation value.

This creates a strong incentive for restructuring rather than immediate liquidation in suitable cases.

39. Aziz v Caixa d'Estalvis de Catalunya — CJEU, C-415/11

Aziz concerned unfair terms in a Spanish consumer mortgage and the effectiveness of consumer protection under Directive 93/13/EEC.

It is not a technology-finance case.

However, if a self-assembly technology business offers financing directly to consumers, Aziz illustrates the broader principle that contractual enforcement cannot override mandatory EU consumer-protection rules.

For ordinary business-to-business R&D financing, the case has little direct relevance.

40. Banco Español de Crédito — CJEU, C-618/10

This case also concerned Spanish consumer contracts and unfair terms.

Its relevance to self-assembling technology finance is similarly limited to situations involving consumer financing.

It should not be treated as authority governing sophisticated corporate technology loans.

41. Key Case-Law Authorities

These authorities concern the legal components surrounding technology financing. They are not Spanish cases directly deciding a bank loan for a “self-assembling technology company.”

42. Example: Spanish Nanotechnology Company

Assume a Spanish company develops self-assembling nanomaterials for electronics.

Total commercialisation requirement:

€80 million

Financing:

• Venture capital: €25m
• Public R&D support: €15m
• EIB/institutional facility: €20m
• Commercial bank debt: €20m

The bank investigates:

Technology: Has it been independently validated?

IP: Does the company own the patents?

Regulation: Does REACH apply?

Customers: Are there binding contracts?

State aid: Is public support legally compliant?

Export controls: Are products dual-use?

Environment: Are nanoparticles safely handled?

Security: What can the bank actually enforce against?

Only then can the bank determine an appropriate lending structure.

43. Lender Security Package

Depending on the project, security might include:

• company shares;
• bank accounts;
• receivables;
• manufacturing equipment;
• patents/IP rights where legally appropriate;
• insurance proceeds;
• material contracts;
• real estate.

Banks should generally avoid assuming that speculative patents alone provide adequate recovery.

44. Conditions Precedent

Before lending, a bank may require:

1. corporate approvals;
2. evidence of equity investment;
3. IP ownership report;
4. patent/legal opinion;
5. regulatory permits;
6. environmental approvals;
7. public-grant documentation;
8. State-aid analysis;
9. key customer contracts;
10. insurance;
11. security perfection;
12. export-control assessment.

Further drawdowns may depend on technical milestones.

45. Main Risks

46. Appropriate Financing by Development Stage

This progression is important because highly experimental scientific risk is generally difficult to finance with ordinary senior bank debt.

47. Conclusion

Self-assembling technology finance in Spain is not a separate category of banking law. It is a specialised form of deep-tech financing governed by ordinary Spanish banking law together with the legal regime applicable to the particular technology.

The principal legal layers include:

• Law 10/2014 and Spanish/EU prudential banking rules;
• Spanish Patent Law 24/2015;
• EU biotechnology and patent principles;
• EU State-aid law;
• REACH and product regulation;
• medical-device rules where applicable;
• the EU AI Act where qualifying AI systems are involved;
• foreign-investment screening;
• EU Dual-Use Regulation 2021/821;
• environmental regulation; and
• Spanish insolvency law.

The most useful cases include Huawei v ZTE, Brüstle v Greenpeace, International Stem Cell, Altmark, PreussenElektra, Stardust Marine and EDF. They provide principles concerning IP, biotechnology and public financing, rather than constituting direct precedents about self-assembling-technology bank loans.

For banks, the central principle is that scientific potential is not equivalent to bankable cash flow. Early projects usually require equity, grants and risk-sharing mechanisms. Conventional debt becomes more appropriate as the technology moves from research → prototype → pilot → regulatory approval → commercial production, with protected IP, credible customers and predictable revenues.